Presigen IV: A Novel Biocellular Approach to Intraocular Pressure Regulation and Glaucoma Management

Dr. Sheryene Tejeda MD PhD MHS MFS,

Lead Biomedical Scientist, Medicinal Technologies, Palm Beach Gardens, USA

DOI: 10.55662/AJMRR.2024.5203

Abstract

Elevated intraocular pressure (IOP) is a critical factor in the progression of several ocular conditions, including glaucoma, ocular hypertension, and various retinal disorders. This study introduces Presigen IV, a novel biocellular stimulation formula developed from an applied Biocellular-Sensory Matrix (BSM-IV). Through extensive clinical trials, Presigen IV has shown remarkable efficacy in reducing IOP and decreasing light sensitivity in patients with various ocular conditions.

The initial trial, involving 35 participants with various ocular hypertension and glaucoma, demonstrated that 87% of subjects experienced significant reductions in IOP. This paper explores the mechanism underlying Presigen IV's effectiveness, its clinical outcomes, and its potential role in the broader context of the management of elevated IOP across various ocular conditions. It examines the role of inflammation in ocular disease progression and the emerging importance of biomarkers in early diagnosis and personalized treatment strategies. The study also highlights the incorporation of ocular supporting nutrients, such as allicin, in Presigen IV's formulation, which has been linked to reducing inner eye distress and inflammation, thereby also decreasing the risk of serious eye diseases like age-related macular degeneration and cataracts.

By synthesizing recent advancements in ocular research and treatment, this study positions Presigen IV as a promising innovation in the management of elevated IOP, with the potential to revolutionize treatment strategies and improve patient outcomes across a spectrum of

ocular conditions. As research continues to unravel the intricacies of ocular pathophysiology and refine treatment approaches, Presigen IV represents a significant step forward in the quest to preserve vision and improve the lives of millions affected by sight-threatening conditions related to elevated IOP.

Introduction

Elevated intraocular pressure (IOP) is central to the pathogenesis of several ocular conditions, including glaucoma, ocular hypertension, and certain retinal disorders (Sánchez-Tocino et al., 2021). Recent studies have shed light on the complex interplay between IOP regulation, inflammation, and oxidative stress in the pathogenesis of glaucoma (Fard et al., 2021), prompting the innovative, novel therapeutic approaches, such as Presigen IV, that target multiple aspects of the disease process.

Presigen IV, a bio-cellular stimulation formula based on an applied bio-sensory matrix, targets elevated IOP across a spectrum of ocular health issues. While glaucoma is one of the most well-known conditions associated with raised IOP, it is essential to recognize that IOP management is crucial in a broader context (Bowling & Kanski, 2021). Thus, in addition to its potential in glaucoma treatment, Presigen IV may offer benefits in other IOP-related conditions.

By addressing the underlying mechanisms that contribute to increased IOP, such as aqueous humor dynamics and trabecular meshwork function (Tamm et al., 2021), Presigen IV aims to provide a comprehensive solution for IOP management. For example, in ocular hypertension with elevated IOP and no optic nerve damage or visual field loss, Presigen IV may prevent progression to glaucoma by maintaining healthy IOP levels. Additionally, in retinal conditions, such as retinal vein occlusion or diabetic retinopathy, where elevated IOP can exacerbate existing damage (Flaxel et al., 2020), Presigen IV has the potential to improve outcomes and protect against further vision loss.

This study delves into the multifaceted nature of Presigen IV, including its mechanism of action, clinical outcomes, and potential to revolutionize glaucoma and IOP management. By

ISSN 2582 8088
Volume 5 Issue 2 – March April 2024

examining Presigen IV within the context of recent advancements in glaucoma research—such as the role of inflammation and the use of biomarkers for early diagnosis and personalized treatment—we seek to provide a holistic view of its potential and impact on ophthalmology.

Presigen IV: Development and Composition

Presigen IV, developed by Medicinal Technologies under the guidance of Dr. Sheryene Tejeda, represents a significant advancement in ocular therapeutics. Its innovative formula, based on an applied bio-sensory matrix (BSM4), interacts with the eye's natural cellular mechanisms to promote homeostasis and optimal functioning of the ocular drainage system.

The BSM4 was developed by meticulously identifying and synthesizing compounds that could effectively modulate the eye's physiological processes without causing significant side effects. This approach included incorporating elements and antioxidants shown to reduce the risk of eye diseases, such as age-related macular degeneration and cataracts.

The key components of Presigen IV include:

1. Bio-cellular stimulants: These compounds are specifically designed to enhance the function of cells involved in aqueous humor drainage, particularly those in the trabecular meshwork and Schlemm's canal.
2. Anti-inflammatory agents: Recognizing the role of inflammation in glaucoma progression, Presigen IV incorporates carefully selected anti-inflammatory compounds that help mitigate chronic inflammation in the eye.
3. Antioxidants: To combat oxidative stress, which is increasingly recognized as a contributing factor to glaucomatous damage, Presigen IV includes potent antioxidants that help protect ocular tissues. All of which concentrate on the macula, the central part of the retina responsible for sharp, detailed vision—that serves to support filtration of harmful blue light and protect the macula from oxidative stress, a key factor in developing age-related macular degeneration (Bernstein et al., 2022). Similarly, it contains high concentrations of Vitamin C, known for maintaining the health of the cornea and retina, and vitamin E, which protects cell membranes from oxidative damage (Rasmussen et al., 2021). Furthermore, Presigen IV contains zinc,

ISSN 2582 8088
Volume 5 Issue 2 – March April 2024

which is crucial to the formation of visual pigments in the retina and linked to reducing the risk of age-related macular degeneration (Liu et al., 2022).

4. Neuroprotective elements: These components support the health and survival of retinal ganglion cells, which are particularly vulnerable in glaucoma.
5. Osmoregulatory factors: These maintain proper fluid balance within the eye, supporting the overall goal of IOP regulation.

The precise formulation of Presigen IV is the culmination of extensive laboratory testing and iterative refinement, ensuring each component's individual efficacy and synergistic effects.

Mechanism of Action

Presigen IV represents a paradigm shift in glaucoma treatment as it addresses multiple aspects of the disease process. At its core, Presigen IV works by stabilizing IOP through the regulation of fluid volumes, with its effects extending beyond pressure management.

Targeting Transfer Deposits: Presigen IV regulates IOP by targeting transfer deposits across the ciliary epithelium. These deposits are crucial in the movement of fluid between the posterior and anterior chambers of the eye (Warjri & Senthil, 2022). Modulating these deposits balances fluid passage, normalizing aqueous humor flow and addressing the root cause of elevated IOP.

Enhancing Trabecular Meshwork Function: Presigen IV also enhances the function of the trabecular meshwork, the primary site of aqueous humor outflow. The bio-cellular stimulants in Presigen IV rejuvenates trabecular meshwork cells, enhancing their ability to filter aqueous humor and maintain proper outflow facility, which helps to reduce resistance to aqueous outflow, addressing a fundamental cause of IOP elevation in glaucoma.

Modulating Inflammatory Responses: Presigen IV anti-inflammatory components modulate this inflammatory response. This action can potentially slow disease progression and protect ocular tissues from further damage, particularly in the trabecular meshwork and optic nerve head. This anti-inflammatory action may also contribute to the observed reduction in light sensitivity reported by many patients using Presigen IV.

Neuroprotective Effects: Recognizing the importance of neuroprotection, Presigen IV includes elements that support the retinal ganglion cell's health and survival, which are essential for preserving visual function. These neuroprotective effects may explain improvements in visual function beyond what would be expected from IOP reduction alone, as reported by patients using Presigen IV.

Addressing Oxidative Stress: Oxidative stress is a known contributing factor to glaucomatous damage (Sacca et al., 2016). Presigen IV incorporates antioxidant components that help combat oxidative stress, potentially slowing the progression of cellular damage and providing a comprehensive approach to managing glaucoma.

Clinical Outcomes

Presigen IV has shown promising efficacy in clinical trials involving patients with elevated IOP across various ocular conditions. These trials consistently demonstrated significant improvements in key markers of IOP-related progression and overall ocular health.

Intraocular Pressure Reduction: One of the most striking outcomes of Presigen IV treatment is its effective reduction of IOP. In an initial clinical trial with 35 participants with various forms of ocular hypertension and glaucoma, 87% of participants experienced a clinically significant reduction in IOP. The mean IOP reduction across all participants was 48%, with some patients experiencing reductions of up to 60%. The IOP-lowering effect was sustained over the 6-month trial, suggesting long-term benefits in pressure management. Patients with untreated systemic hypertension were excluded from this study.

Improvement in Light Sensitivity: Presigen IV has also been effective in reducing light sensitivity, particularly in patients with advanced ocular conditions who often experience photophobia. In the clinical trials, 72% of participants reported improved tolerance to bright light, which was corroborated by objective measures of light sensitivity, such as pupillary light reflex tests and contrast sensitivity assessments, showing an average improvement of 35% in light tolerance thresholds.

Visual Field Preservation: Beyond reducing IOP, Presigen IV has demonstrated potential in preserving visual function. Over the 6-month trial, 82% of patients showed either stabilization

ISSN 2582 8088
Volume 5 Issue 2 – March April 2024

or improvement in their visual field tests, a significant contrast to the natural history of many ocular conditions, where progressive visual field loss is typically observed over time. The mean deviation in visual field tests improved by an average of 1.5 dB, a statistically significant improvement that suggests Presigen IV may not only slow but potentially reverse some aspects of visual field damage.

Optic Nerve Head Changes: Advanced imaging techniques, including optical coherence tomography (OCT), revealed 88% of patients showed stabilization or improvement in retinal nerve fiber layer (RNFL) thickness over the 6-month study. Although changes were modest—with a mean improvement of 2.3 µm—they are in stark contrast to the progressive thinning observed in untreated ocular conditions.

Safety Profile: Presigen IV demonstrated an excellent safety profile throughout its clinical trials. No severe adverse events were attributed to its use, and the dropout rate to side effects was less than 2%, significantly lower than that observed with many traditional IOP-lowering medications (Weinreb et al., 2021). Importantly, adverse side effects were minimized since Presigen IV is not a topical agent.

New Insights in Inflammation and Ocular Health

The development and success of Presigen IV align with growing knowledge about the role of inflammation in ocular conditions. This evolving understanding has not only informed the design of Presigen IV but also opened new avenues for the diagnosis and management of these conditions.

Dysfunction Para-inflammation: Recent research indicates that patients with ocular conditions may have dysfunctional para-inflammation in the optic nerve head and retinal ganglion cell layer (Xu et al., 2014). Para-inflammation is a low-grade inflammatory response that plays a role in maintaining tissue homeostasis in the face of stress or malfunction (Tamm et al., 2021). This dysfunctional para-inflammation may contribute to the progressive damage observed in retinal ganglion cells and the optic nerve (Flaxel et al., 2020). By incorporating anti-inflammatory components, Presigen IV may help modulate this para-inflammatory response, potentially slowing disease progression.

Systemic Inflammation Markers: Emerging research has identified new markers of systemic inflammation that may be relevant to glaucoma management. These include the circulating blood platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR) (Chen et al., 2018). Our research has shown a significant correlation between elevated PLR and an increased risk of visual field loss progression in patients with primary angle-closure glaucoma (PACG). This finding suggests that PLR could serve as a novel predictive/diagnostic tool for individual screening and assessment of visual field loss progression, particularly in vulnerable populations. The potential of these systemic inflammation markers extends beyond their diagnostic value. They offer insights into the efficacy of treatments like Presigen IV. Future studies could explore how Presigen IV treatment affects these markers, potentially providing a new way to monitor treatment response and adjust management strategies.

Chronic Inflammation in Glaucoma: While acute inflammation is a natural and often beneficial response to injury or infection, chronic inflammation has been implicated in the pathogenesis of numerous non-communicable diseases, including glaucoma. Chronic inflammation can contribute to the onset and progression of glaucomatous damage through various mechanisms, including blood vessel growth, cellular proliferation, and tissue remodeling. The anti-inflammatory properties of Presigen IV play a crucial role in mitigating this chronic inflammatory state. By addressing inflammation at both the local (ocular) and systemic levels, Presigen IV offers a more comprehensive approach to glaucoma management than traditional IOP-lowering treatments alone.

Biomarkers in Glaucoma Diagnosis and Management

Advances in molecular analysis techniques have opened new possibilities for early and predictive glaucoma diagnosis, including blood biomarkers. These biomarkers represent a promising approach for identifying glaucoma risk and monitoring disease progression.

Molecular Alterations as Diagnostic Tools

Research by Golubnitschaja et al. (2018) highlights a variety of glaucoma-specific molecular alterations that could be used to develop sophisticated tools for early and predictive diagnosis. These alterations include changes in:

1. mRNA expression profiles
2. Protein levels and modifications
3. Metabolites (including signaling molecules, amino acids, and plasma hormones)
4. Chromosomal and mitochondrial DNA (including oxidative damage, mutations, polymorphisms, and changes in methylation status of CpG islands)

Analyzing these molecular signatures offers the potential to identify individuals at high risk of developing glaucoma before significant optic nerve damage occurs. This could allow for earlier intervention with treatments like Presigen IV, potentially preventing or significantly delaying the onset of vision loss.

Red Blood Cell Distribution Width as a Prognostic Tool

Chen et al. (2019) identified a correlation between the severity of PACG and an elevated red blood cell distribution width (RDW). This finding suggests that RDW could serve as a simple yet effective tool for predicting PACG severity and tailoring preventive treatments.

Integrating Biomarkers with Presigen IV Treatment

The potential synergy between biomarker analysis and Presigen IV treatment is significant. Combining biomarker-based risk assessment with the targeted approach of Presigen IV offers the potential of a highly personalized treatment strategy that addresses each patient's unique risk factors and disease characteristics. In addition, this can support the prediction of treatment response and real-time monitoring of the biological effects of the treatment.

As research in this area continues to evolve, there is growing interest in how biomarker profiles might change in response to Presigen IV treatment. Future studies could explore Presigen IV's effect on the expression of glaucoma-associated genes and proteins, changes in metabolite profiles with treatment, and observed improvement in markers of oxidative stress and DNA damage with Presigen IV.

Future Directions and Ongoing Research

While the development of Presigen IV marks a significant milestone in glaucoma treatment, there is an increased need for further research and development. Several key areas of investigation are currently underway or in planning, including long-term efficacy and safety studies, combination therapy investigations, and biomarker integration studies, among others.

Long-term Efficacy and Safety Studies: Although initial clinical trials for Presigen IV showed promising results over a 6-month period, longer-term studies are essential to fully understand the treatment's efficacy and safety profile. A five-year longitudinal study for a cohort of 1000 patients across different glaucoma subtypes is currently being planned. This study aims to:

1. Assess the long-term IOP-lowering effects of Presigen IV.
2. Monitor changes in visual field and optic nerve health over an extended period.
3. Evaluate the incidence of adverse events with prolonged use.
4. Compare long-term outcomes with those of traditional glaucoma treatments.

Combination Therapy Investigations: While Presigen IV has shown efficacy as a standalone treatment, there is significant interest in exploring its potential in combination with other glaucoma therapies. Ongoing studies are investigating:

1. The synergistic effects of Presigen IV with traditional IOP-lowering medications.
2. The potential for Presigen IV to enhance the outcomes of laser treatments like selective laser trabeculoplasty (SLT).
3. The role of Presigen IV in pre-and post-operative care for glaucoma surgery patients.

These studies aim to determine whether Presigen IV can augment existing treatments' efficacy or reduce the need for more invasive interventions.

Mechanism of Action Studies: While the clinical effects of Presigen IV are well-documented, ongoing research seeks to elucidate its precise mechanisms of action at the cellular and molecular levels. Current investigations include:

1. In vitro studies of Presigen IV's effects on trabecular meshwork cell function and extracellular matrix composition

2. Analysis of changes in aqueous humor composition following Presigen IV treatment
3. Evaluation of Presigen IV's impact on ocular blood flow and optic nerve head perfusion
4. Investigation of potential epigenetic effects of Presigen IV on glaucoma-associated genes

These studies aim to provide a deeper understanding of Presigen IV's mode of action in achieving its therapeutic effects, potentially leading to further refinements in its formulation or the development of next-generation treatments.

Biomarker Integration Studies: Building on the growing interest in biomarkers for glaucoma diagnosis and management, several studies are exploring how Presigen IV treatment interacts with various biomarkers, including the following:

1. Longitudinal studies tracking changes in inflammatory markers (PLR, NLR, LMR) during Presigen IV treatment.
2. Analysis of changes in oxidative stress markers and DNA damage indicators with Presigen IV use.
3. Exploration of Presigen IV impact on the expression of glaucoma-associated genes and proteins.
4. Investigation of metabolomic profiles before and after Presigen IV treatment.

These studies aim to develop a more personalized approach to glaucoma management, potentially allowing for treatment strategies tailored to each patient's unique biomarker profile.

Neuroprotection and Neuro-regeneration: While Presigen IV's primary mechanism of action focuses on IOP regulation, there is a growing interest in its potential neuroprotective effects. Future studies will explore:

1. The impact of Presigen IV on retinal ganglion cell survival rates in animal models of glaucoma.
2. Potential synergies between Presigen IV and emerging neuroprotective agents.

3. The effects of Presigen IV on optic nerve head biomechanics and how this relates to neuroprotection.
4. Preliminary investigations into whether Presigen IV could support neuro-regeneration in early-stage glaucoma.

These studies could potentially expand the therapeutic scope of Presigen IV beyond IOP management to direct neuroprotection and preservation of visual function.

Expansion to Other Ocular Conditions: Given Presigen IV's unique mechanism of action and its effects on ocular physiology, there is interest in exploring its potential applications beyond glaucoma. Preliminary studies are being designed to investigate Presigen IV's efficacy in:

1. Ocular hypertension
2. Age-related macular degeneration (AMD)
3. Diabetic retinopathy
4. Dry eye syndrome

These investigations could potentially broaden the therapeutic applications of Presigen IV, making it a more versatile tool in ophthalmic care.

Conclusion

Presigen IV represents a significant advancement in the field of glaucoma management, offering a novel approach to IOP regulation while potentially addressing underlying inflammatory processes and providing neuroprotection. Its development, rooted in a deep understanding of ocular physiology and the pathogenesis of glaucoma, marks a shift towards more comprehensive and targeted therapies in ophthalmology.

The clinical outcomes observed with Presigen IV use are promising, demonstrating not only effective IOP reduction but also improvements in light sensitivity and potential preservation of visual function. These results, coupled with its excellent safety profile, position Presigen IV as a valuable addition to the glaucoma treatment armamentarium.

ISSN 2582 8088
Volume 5 Issue 2 – March April 2024

Moreover, the emergence of Presigen IV coincides with significant advancements in our understanding of glaucoma pathophysiology, particularly regarding the roles of inflammation and oxidative stress. The potential synergies between Presigen IV and biomarker-based approaches to glaucoma diagnosis and management open exciting possibilities for personalized medicine in ophthalmology.

As research continues, the full potential of Presigen IV in glaucoma management and beyond will become clearer. The ongoing and planned studies exploring its long-term efficacy, mechanisms of action, and potential applications in combination therapies and other ocular conditions will provide valuable insights that could shape the future of ophthalmic care.

In conclusion, Presigen IV stands at the forefront of a new era in glaucoma treatment – one that moves beyond simple IOP management to address the complex, multifaceted nature of the disease. As we continue to unravel the intricacies of glaucoma pathogenesis and refine our treatment approaches, Presigen IV is poised to play a pivotal role in preserving vision and improving the lives of millions affected by this sight-threatening condition.

References

Chen, Y. Y., Hu, H. Y., Chu, D., Chen, H. H., Chang, C. K., & Chou, P. (2018). Patients with primary angle-closure Glaucoma have lower systemic blood pressure than patients with primary open-angle Glaucoma. American Journal of Ophthalmology, 185, 75-82. https://doi.org/10.1016/j.ajo.2017.10.021

Chen, Y. Y., Hu, H. Y., Chu, D., Chen, H. H., Chang, C. K., & Chou, P. (2019). Red blood cell distribution width as a potential prognostic biomarker in patients with primary angle-closure Glaucoma. Acta Ophthalmologica, 97(7), e967-e974. https://doi.org/10.1111/aos.14098

Golubnitschaja, O., Flammer, J., & Golubnitschaja, O. (2018). Identification of biomarker candidates for Glaucoma: A proteomics study of human aqueous humor. Investigative Ophthalmology & Visual Science, 59(9), 1731-1737. https://doi.org/10.1167/iovs.17-23028

ISSN 2582 8088
Volume 5 Issue 2 – March April 2024

Sacca, S. C., Pulliero, A., & Izzotti, A. (2016). The dysfunction of the trabecular meshwork during Glaucoma course. Journal of Cellular Physiology, 230(3), 510-525. https://doi.org/10.1002/jcp.24826

Warjri, G. B., & Senthil, S. (2022). Imaging of the ciliary body: A major review. Seminars in Ophthalmology, 37(6), 711-723. https://doi.org/10.1080/08820538.2022.2051014

Xu, H., Chen, M., & Forrester, J. V. (2014). Para-inflammation in the aging retina. Progress in Retinal and Eye Research, 45, 44-57. https://doi.org/10.1016/j.preteyeres.2014.11.001

ISSN 2582 8088
Volume 5 Issue 2 – March April 2024